Related Experiment Videos
Effect of prazosin treatment on HDL kinetics in patients with hypertension
W H Sheu1, A L Swislocki, B B Hoffman
1Department of Medicine, Stanford University School of Medicine, California.
Insights
Prazosin treatment significantly lowered blood pressure and increased HDL-cholesterol in patients with mild hypertension. This hypertension drug also normalized abnormal HDL kinetics, suggesting clinical benefit for mild hypertension.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Mild hypertension is associated with abnormalities in high-density lipoprotein (HDL) cholesterol concentration and HDL kinetics.
- These lipid abnormalities may contribute to cardiovascular risk in hypertensive individuals.
Purpose of the Study:
- To investigate the effects of prazosin treatment on blood pressure, plasma HDL-cholesterol, and apoprotein-AI/HDL (apoAI/HDL) kinetics in patients with mild hypertension.
Main Methods:
- 11 patients with mild hypertension received prazosin treatment for 4-5 months.
- Measurements included blood pressure, plasma HDL-cholesterol concentration, and apoAI/HDL kinetics (fractional catabolic rate [FCR] and total synthetic rate).
- Nonlinear curve fitting was used to analyze the 125I-AI/HDL disappearance curve.
Main Results:
- Prazosin treatment significantly reduced blood pressure (143/96 to 134/86 mm Hg) and increased plasma HDL-cholesterol (38 to 46 mg/dL).
- Both FCR and total synthetic rate of apoAI/HDL decreased significantly, returning to normal ranges.
- Analysis of decay curves indicated normalization of apoAI/HDL FCR was due to decreased decay constants.
Conclusions:
- Patients with mild hypertension exhibit abnormal HDL concentration and kinetics.
- Prazosin treatment effectively improved these lipid abnormalities, suggesting its potential clinical utility in managing mild hypertension.
Abstract:
The effect of prazosin treatment on blood pressure, plasma HDL-cholesterol concentration, and apoprotein-AI/HDL (apoAI/HDL) kinetics was studied in 11 patients with mild hypertension. Blood pressure (mean +/- SEM) fell from 143 +/- 1/96 +/- 1 to 134 +/- 1/86 +/- 1 mm Hg after 4 to 5 months of prazosin treatment (P less than .001), associated with an increase in plasma HDL-cholesterol concentration from 38 +/- 2 to 46 +/- 2 mg/dL (P less than .001). Both the fractional catabolic rate (FCR) and total synthetic rate of apoAI/HDL, which were higher than previous reported values for normal individuals, decreased from 0.36 +/- 0.02 to 0.30 +/- 0.02 L/day and 17.4 +/- 1.1 to 13.8 +/- 1.1 mg/kg/min, respectively. These changes were statistically significant, and the post-treatment values for both variables were now within the normal range. When the decay curve was further analyzed by nonlinear curve fitting, it was shown that the return to normal of the FCR of apoAI/HDL in patients treated with prazosin was accounted for by the decrease of the decay constants of the second [p(2)] and third [p(3)] components of the 125I-AI/HDL disappearance curve. In conclusion, abnormalities in HDL concentration and HDL kinetics exist in patients with very mild hypertension. These defects were significantly improved with prazosin treatment, and this may render the compound of particular clinical benefit in the treatment of patients with mild hypertension.